Joy Read1, Rebecca Jones2, Gail Owen1, Blair R Leavitt3, Allison Coleman3, Raymund A C Roos4, Eve M Dumas4, Alexandra Durr5, Damian Justo5, Miranda Say1, Julie C Stout6, Sarah J Tabrizi1, David Craufurd7. 1. UCL Institute of Neurology, University College London, Queen Square, London, UK. 2. London School of Hygiene and Tropical Medicine, London, UK. 3. Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 4. Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. 5. Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France. 6. School of Psychology, Psychiatry, and Psychological Medicine, Monash University, Clayton Campus, VIC, Australia. 7. University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Abstract
BACKGROUND: Given the multifaceted nature of this inherited neurodegenerative condition, typically affecting adults in mid-life, it is perhaps not surprising that studies indicate poorer Health Related Quality of Life (HrQoL) in those with the gene-expansion and, by association, in their families. OBJECTIVE: This study aimed to extend the current literature by exploring specific life domains, including at an earlier disease stage than usually reported in the HRQoL literature, and in a subgroup of gene-negative partners. METHODS: 355 participants from the TRACK-HD cohort (120 Controls, 118 Pre-HD and 117 early-HD) completed standardised self-report measures of HrQoL (SF36 and QoLI), underwent clinical assessments of capacity and motor function (UHDRS), semi structured interviews assessing neuropsychiatric symptoms (PBA-s), completed paper and computerized cognitive tasks and assessment of behaviours associated with damage to frontal brain circuits (FrSBe). RESULTS: Each gene-expanded group scored statistically significantly lower than gene-negative sibling controls on the SF36 General Health subscale; neuropsychiatric symptoms and executive dysfunction were associated with reduced HrQoL. Those with Stage II disease reported statistically significantly lower HrQoL than gene-negative controls across physical, emotional and social life domains. Those partnered with manifest participants reported lower HrQoL in the social domain compared to those partnered with at-risk participants furthest from disease onset; and perseverative symptoms in manifest partners were found to be related to lower HrQoL in their gene-negative partners. HrQoL in gene-negative partners of pre-manifest individuals was associated with pre-manifest individuals' neuropsychiatric and cognitive function. CONCLUSIONS: Understanding the nature and timing of disruption to the HrQoL in people who are pre-manifest and diagnosed with HD, and their gene-negative partners, can inform the development of appropriate strategies and interventions.
BACKGROUND: Given the multifaceted nature of this inherited neurodegenerative condition, typically affecting adults in mid-life, it is perhaps not surprising that studies indicate poorer Health Related Quality of Life (HrQoL) in those with the gene-expansion and, by association, in their families. OBJECTIVE: This study aimed to extend the current literature by exploring specific life domains, including at an earlier disease stage than usually reported in the HRQoL literature, and in a subgroup of gene-negative partners. METHODS: 355 participants from the TRACK-HD cohort (120 Controls, 118 Pre-HD and 117 early-HD) completed standardised self-report measures of HrQoL (SF36 and QoLI), underwent clinical assessments of capacity and motor function (UHDRS), semi structured interviews assessing neuropsychiatric symptoms (PBA-s), completed paper and computerized cognitive tasks and assessment of behaviours associated with damage to frontal brain circuits (FrSBe). RESULTS: Each gene-expanded group scored statistically significantly lower than gene-negative sibling controls on the SF36 General Health subscale; neuropsychiatric symptoms and executive dysfunction were associated with reduced HrQoL. Those with Stage II disease reported statistically significantly lower HrQoL than gene-negative controls across physical, emotional and social life domains. Those partnered with manifest participants reported lower HrQoL in the social domain compared to those partnered with at-risk participants furthest from disease onset; and perseverative symptoms in manifest partners were found to be related to lower HrQoL in their gene-negative partners. HrQoL in gene-negative partners of pre-manifest individuals was associated with pre-manifest individuals' neuropsychiatric and cognitive function. CONCLUSIONS: Understanding the nature and timing of disruption to the HrQoL in people who are pre-manifest and diagnosed with HD, and their gene-negative partners, can inform the development of appropriate strategies and interventions.
Entities:
Keywords:
Huntington's disease; TRACK-HD; cognitive function; life domains; neuropsychiatric function; quality of life
Authors: Hosung Kim; Ji-Hoon Kim; Katherine L Possin; Joseph Winer; Michael D Geschwind; Duan Xu; Christopher P Hess Journal: Brain Imaging Behav Date: 2017-10 Impact factor: 3.978
Authors: Noelle E Carlozzi; Elizabeth A Hahn; Siera M Goodnight; Anna L Kratz; Jane S Paulsen; Julie C Stout; Samuel Frank; Jennifer A Miner; David Cella; Richard C Gershon; Stephen G Schilling; Rebecca E Ready Journal: Psychol Assess Date: 2017-05-29
Authors: Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi Journal: Qual Life Res Date: 2017-12-06 Impact factor: 4.147
Authors: Nora E Fritz; Nicholas R Boileau; Julie C Stout; Rebecca Ready; Joel S Perlmutter; Jane S Paulsen; Kimberly Quaid; Stacey Barton; Michael K McCormack; Susan L Perlman; Noelle E Carlozzi Journal: J Neuropsychiatry Clin Neurosci Date: 2018-03-21 Impact factor: 2.198
Authors: N E Carlozzi; N R Downing; S G Schilling; J-S Lai; S M Goodnight; J A Miner; S A Frank Journal: Qual Life Res Date: 2016-05-03 Impact factor: 4.147
Authors: Marleen R van Walsem; Emilie I Howe; Gunvor A Ruud; Jan C Frich; Nada Andelic Journal: Health Qual Life Outcomes Date: 2017-01-07 Impact factor: 3.186